Abstract:IMPORTANCE:Studies of the use of gonadotropin-releasing hormone analogs (GnRHa) to protect ovarian function have shown mixed results.OBJECTIVE:To determine whether administering GnRHa during chemotherapy in premenopausal women with breast cancer can reduce ovarian impairment.DESIGN, SETTING, AND PARTICIPANTS:This randomized clinical trial, conducted at the Shanghai Jiao Tong University Affiliated Shanghai Sixth People's Hospital and Zhejiang Cancer Hospital in China, was an open-label trial involving premenopausal women aged 18 to 49 years with operable stage I to III breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned in 2 parallel groups: treatment with chemotherapy with or without GnRHa. Enrollment occurred from September 2015 to August 2017, and follow-up ended December 2020. The data were analyzed in March 2021. A total of 405 patients were enrolled in the study, among whom 27 patients (6.7%) quit participation voluntarily, 33 (8.1%) did not meet the inclusion criteria and were excluded, and 15 (3.7%) were lost to follow-up. Ultimately 330 patients were included in the primary analysis, including 29 patients with baseline anti-Müllerian hormone levels less than 0.5ng/ mL.INTERVENTIONS:Eligible patients were randomly assigned (1:1) to receive chemotherapy with (n = 165) or without (n = 165) GnRHa. In patients randomized to receive GnRHa, 3.6 mg of goserelin or 3.75 mg of leuprorelin was injected subcutaneously once every 28 days from 1 to 2 weeks before the first cycle of chemotherapy to 4 weeks after the last cycle of chemotherapy.MAIN OUTCOMES AND MEASURES:The primary end point was the rate of premature ovarian insufficiency (POI) at 12 months after chemotherapy. Premature ovarian insufficiency was defined as anti-Müllerian hormone levels of less than 0.5 ng/mL in this study. The secondary end point was overall survival (OS) and tumor-free survival (TFS).RESULTS:A total of 330 eligible patients could be evaluated with complete data, among whom 301 patients (91.2%; GnRHA group: mean [SD] age, 40.6 [6.7] years; control group: mean [SD] age, 40.2 [5.9] years) were eligible for primary end point analysis. At 12 months after the completion of chemotherapy, the POI rate was 10.3% (15 of 146) in the GnRHa group and 44.5% (69 of 155) in the control group (odds ratio, 0.23; 95% CI, 0.14-0.39; P < .001). Anti-Müllerian hormone resumption in the GnRHa group was significantly better than that in the control group (15 of 25 vs 6 of 44; odds ratio, 4.40; 95% CI, 1.96-9.89; P < .001). After a median follow-up of 49 months (range, 25-60 months), the differences in 4-year OS and TFS between the 2 groups were not significant. A post hoc analysis showed that in patients younger than 35 years, the TFS was higher in the GnRHa group than in the control group (93% vs 62%; P = .004; hazard ratio, 0.15; 95% CI, 0.03-0.82; P = .03).CONCLUSIONS AND RELEVANCE:This randomized clinical trial found that administering GnRHa in treatment with chemotherapy for premenopausal patients with breast cancer reduces the risk of POI, which promotes the recovery of ovarian function.TRIAL REGISTRATION:ClinicalTrials.gov Identifier: NCT02518191.

The effect of chemotherapy on ovarian function in patient with ovarian carcinoma undergoing preservation operation

Effect of chemotherapy on ovarian reserve in premenopausal patients with breast cancer

Impact of Chemotherapy on Ovarian Function of Patients with Malignant Tumor

Long-term effect of chemotherapy after ovarian decortication on the ovarian function in women surviving cancer

The effect of chemotherapy in patients with stage I mucinous ovarian cancer undergoing fertility-sparing surgery

The Effect of Chemotherapy on Gonadal Hormone Levels of the Breast Cancer Patients During Perimenopausal Period

Multicenter randomized controlled clinical study for the operative treatment of malignant ovarian germ cell tumors

Gonadotropin-releasing Hormone Agonists Cotreatment During Chemotherapy in Borderline Ovarian Tumor and Ovarian Cancer Patients.

Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: A retrospective study and meta-analysis.

Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study.

Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer

Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China

Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women with Breast Cancer in China: A Randomized Clinical Trial.

Ovarian function reservation and chemotherapy after surgery for ovarian cancer

Protecting Effects of Gonadotropin-Releasing Hormone Agonist on Chemotherapy-Induced Ovarian Damage in Premenopausal Breast Cancer Patients: A Systematic Review and Meta-Analysis

The Application of Gonadotropin-Releasing Hormone Agonists in Non-Malignant Ovarian Tumor Patients

The survival effect of ovary preservation in early stage endometrial cancer: a single institution retrospective analysis

Observation and Clinical Significance of Adjuvant Chemotherapy-Induced Amenorrhea in Pre-Menopausal Breast Cancer Patients

Effect of Zoladex administered before chemotherapy on menstruation of patients with breast cancer

Effects of Different Prescriptions for Reinforcing Kidney on Chemotherapy-Induced Premature Ovarian Failure

Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.